Product Description
PTH 1-34 Bone-Anabolic Research Peptide
Teriparatide is a synthetic recombinant peptide consisting of the first 34 amino acids of human parathyroid hormone (PTH 1-34). It is studied for its anabolic effects on skeletal tissue and its ability to stimulate osteoblast activity, new-bone formation, bone remodeling, and changes in bone-mineral density.
Unlike antiresorptive approaches that primarily investigate mechanisms associated with slowing bone breakdown, Teriparatide is notable for its bone-anabolic signaling profile. Research examines how intermittent PTH 1-34 receptor stimulation can preferentially support osteoblast development, activity, and skeletal matrix formation.
Teriparatide has been extensively investigated in the context of postmenopausal osteoporosis, primary osteoporosis, hypogonadal osteoporosis in men, and glucocorticoid-induced bone loss. These research frameworks focus on changes in bone density, skeletal quality, microarchitecture, and fracture-associated outcomes.
Structural bone research involving PTH 1-34 examines both trabecular and cortical bone compartments. Experimental and clinical models evaluate changes in bone thickness, internal architecture, mineralization, and overall mechanical strength, particularly within skeletal regions such as the spine and hip.
The intermittent nature of Teriparatide-associated signaling is an important area of study. Repeated short-duration PTH exposure can produce a different biological response than continuous parathyroid-hormone elevation, providing a model for examining how pulsatile endocrine signaling influences the balance between bone formation and bone resorption.
Key Research Areas
🦴
Osteoblast stimulation and new-bone formation in research examining bone-forming cell activity, proliferation, differentiation, and skeletal matrix production
🧬
PTH 1-34 receptor signaling in laboratory and clinical models examining parathyroid-hormone-associated skeletal responses
📈
Bone-mineral-density research involving changes in skeletal mineral content, density measurements, and structural strength
🏗️
Trabecular and cortical microarchitecture in research examining bone thickness, structural organization, connectivity, and mechanical quality
🔄
Bone remodeling and formation-resorption balance in experimental models examining how anabolic PTH signaling alters normal skeletal turnover
⚡
Intermittent and pulsatile PTH exposure in research examining the distinct skeletal effects of short-duration signaling compared with continuous hormone elevation
👩
Postmenopausal osteoporosis models involving reduced bone density, compromised skeletal strength, and elevated fracture-associated risk
🧪
Primary and hypogonadal osteoporosis research in male skeletal models examining reduced bone mass and altered endocrine signaling
💊
Glucocorticoid-induced bone-loss models examining skeletal deterioration associated with prolonged glucocorticoid exposure
🛡️
Fracture-associated skeletal outcomes in research involving vertebral and non-vertebral bone integrity, skeletal strength, and structural resilience
This 10 mg presentation supports controlled PTH, bone-anabolic, and skeletal-remodeling research designs, making it suitable for investigations across osteoblast activity, new-bone formation, PTH 1-34 signaling, bone-mineral density, trabecular and cortical microarchitecture, skeletal remodeling, intermittent endocrine signaling, osteoporosis, glucocorticoid-associated bone loss, and fracture-related skeletal outcomes.
Intended Use
📦 Format: Lyophilized powder (10mg)
🧬 Compound: Teriparatide / recombinant human PTH 1-34
⚠️ Use: For laboratory research use only. Not for human or veterinary use.
Why Researchers Choose This Compound
🦴
Defined bone-anabolic research relevance supports focused investigation of osteoblast activity, new-bone formation, skeletal matrix development, and bone-strength pathways.
⚡
Intermittent PTH signaling utility provides a framework for studying how pulsatile PTH 1-34 exposure can favor bone-forming activity over continuous hormone-associated responses.
📈
Broad skeletal-structure research value supports investigations involving bone-mineral density, trabecular architecture, cortical thickness, spine structure, hip structure, and mechanical strength.
🔄
Bone-remodeling pathway relevance offers a controlled framework for examining osteoblast-driven formation, normal skeletal turnover, and formation-resorption balance.
🔬
Multiple osteoporosis research frameworks support investigation across postmenopausal, male primary, hypogonadal, and glucocorticoid-associated bone-loss models.
Product Notes
✅ Research category: Bone formation, skeletal remodeling, osteoporosis, and PTH signaling
✅ Study context: Laboratory, preclinical, and skeletal research models
✅ Peptide class: Recombinant human parathyroid hormone fragment PTH 1-34
✅ Anabolic focus: Osteoblast stimulation, new-bone formation, skeletal matrix production, and bone remodeling
✅ Structural focus: Bone-mineral density, trabecular microarchitecture, cortical structure, skeletal thickness, and mechanical strength
✅ Signaling focus: Intermittent PTH receptor activation, pulsatile endocrine signaling, and bone formation-resorption balance
✅ Osteoporosis focus: Postmenopausal, primary, hypogonadal, and glucocorticoid-induced osteoporosis research models
✅ Fracture focus: Vertebral and non-vertebral skeletal integrity, structural resilience, and fracture-associated outcome research
